DIASENSOR COM INC
8-K, 2000-11-14
ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS
Previous: BOCA RESEARCH INC, 10-Q, EX-27, 2000-11-14
Next: DIASENSOR COM INC, 8-K, 2000-11-14




             SECURITIES AND EXCHANGE COMMISSION

                   Washington, D.C.  20549

                          FORM 8-K

                       CURRENT REPORT

           Pursuant to Section 13 or 15(d) of the
               Securities Exchange Act of 1934

                     ___________________


   Date  of Report (Date of earliest event reported) November 13, 2000

                         BICO, INC.
   (Exact name of registrant as specified in its charter)


        Pennsylvania                                      0-10822
(State of other jurisdiction of Incorporation)      (Commission File Number)

                                25-1229323
                    (IRS Employer Identification No.)


             2275 Swallow Hill Road, Bldg. 2500
               Pittsburgh, Pennsylvania 15220
     (Address of principal executive offices)(Zip Code)


Registrant's telephone number, including area code (412) 429-0673


 ___________________________________________________________
               (Former name or former address,
               if changes since last report.)



Item 1.   Change in Control of Registrant.
          Not applicable.

Item 2.   Acquisition or Disposition of Assets.
          Not applicable.

Item 3.   Bankruptcy or Receivership.
          Not applicable.

Item 4.   Changes in Registrant's Certifying Accountant
          Not applicable.

Item 5.   Other Events.
          On   November   14,  2000,  BICO   announced   its
          acceptance  of  David  L. Purdy's  resignation  as
          president  of  its  Biocontrol  Technology,   Inc.
          subsidiary. The Company has commenced a search for
          his replacement.  BICO also confirmed that it has,
          and   will  continue  to,  fund  and  support  the
          Diasensor project (press release attached).

          BICO   acknowledges  that  a  press  release   was
          evidently  issued  by persons  at  its  Biocontrol
          Technology,  Inc. division on November  13,  2000;
          that press release was not authorized by BICO, and
          it  was  not  reviewed in compliance  with  BICO's
          corporate  policy  regarding the dissemination  of
          non-public   information.   As   a   result,   the
          Biocontrol Technology press release dated November
          13, 2000 will not be filed as an exhibit to Form 8-
          K.  BICO  believes  that the press  release  dated
          November  14,  2000,  and attached  hereto  as  an
          exhibit,  properly addresses the issues raised  in
          the November 13, 2000 press release.

Item 6.   Resignation of Registrant's Directors.
          Not Applicable.

Item 7.   Financial Statements, Pro Forma Financial Information and Exhibits.

          (a)  Financial Statements and Business Acquired.
               Not applicable.

          (b)  Pro Forma Financial Information.
               Not applicable.

          (c)  Exhibits.

               Press Release dated November 14, 2000


                         SIGNATURES

     Pursuant to the requirement of the Securities Exchange Act of 1934, the
 Registrant has duly caused this Report to be signed on its behalf by the
 undersigned hereunto duly authorized.




                                   BICO, INC.


                                   By: /s/ Fred E. Cooper
                                           Fred E. Cooper, CEO



DATED:  November 14, 2000






          BICO ACCEPTS RESIGNATION OF DIVISION HEAD


     Pittsburgh, PA - November 14, 2000 - BICO, Incorporated
(OTCBB:BIKO)  announced  today  that  it  has  accepted  the
resignation  of  David  L.  Purdy,  72,  President  of   the
Biocontrol Technology, Inc. division.
      Fred  E.  Cooper, CEO of BICO, said,  "We  regret  the
resignation   of   Mr.  Purdy,  who  has  made   significant
contributions in the development of the noninvasive  glucose
sensor  technology.  However, BICO assures the  shareholders
that it will move swiftly to replace Mr. Purdy and that  the
Diasensor  2000  project  will continue  to  be  funded  and
supported by BICO, as it has since 1989."
      To  date  in year 2000, BICO has funded the  Diasensor
project  in  excess  of  $14 million, which  exceeds  budget
requirements by over $1 million.
     Currently, the Diasensor is in clinical trials designed
and conducted by the Joslin Diabetes Center in Boston.
      To  announce his resignation, Mr. Purdy issued a press
release wherein he also took issue with information recently
released to BICO subsidiary Diasensor.com shareholders.   Of
those comments, Mr. Cooper said, "I feel it is important  to
say  that the Company agrees with Mr. Purdy's comments  that
many  issues  need  to  be addressed  before  the  stock  of
Diasensor.com is liquid, that FDA approval depends upon  the
successful outcome data of the Joslin trials, and  that  the
Diasensor  2000  is not intended for use by  all  diabetics.
BICO has never maintained otherwise.  At this time, however,
the  Company  cannot confirm Mr. Purdy's definition  of  the
market size for the Diasensor."
     BICO, Inc. has its corporate offices in Pittsburgh,  PA
and  is  involved  in  the development  and  manufacture  of
biomedical  devices  and environmental products.  Biocontrol
Technology, Inc., a division of BICO located in Indiana, PA,
focuses  on the research, development, and manufacturing  of
the   Diasensor   noninvasive  glucose  sensor   and   other
biomedical products.
FOR FURTHER INFORMATION, CONTACT:
Investors                                  Media
Diane McQuaide                             Susan Taylor
1.412.429.0673 phone                       1.412.429.0673 phone
1.412.279.9690 fax                         1.412.279.5041 fax

INVESTOR RELATIONS NEWSLINE NUMBER:  1.800.357.6204
WEBSITE:  www.bico.com





© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission